Loading...
Alnylam Pharmaceuticals, Inc.
0HD2.L•LSE
Healthcare
Medical - Pharmaceuticals
£306.29
£8.04(2.70%)
Alnylam Pharmaceuticals, Inc. (0HD2.L) Financial Performance & Statements
Review Alnylam Pharmaceuticals, Inc.’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns to understand its financial health and growth.
Revenue Growth
22.97%
↑ 22.97%
Operating Income Growth
37.31%
↑ 37.31%
Net Income Growth
36.82%
↑ 36.82%
Operating Cash Flow Growth
-107.98%
↓ 107.98%
Operating Margin
-7.87%
↓ 7.87%
Gross Margin
85.62%
↑ 85.62%
Net Profit Margin
-12.37%
↓ 12.37%
ROE
905.33%
↑ 905.33%
ROIC
-5.68%
↓ 5.68%
Alnylam Pharmaceuticals, Inc. (0HD2.L) Financial Statements
Explore quarterly and annual reports including balance sheet, income statement, cash flow for Alnylam Pharmaceuticals, Inc. stock.
| Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Revenue | $593.17M | $500.92M | $659.83M | $494.33M |
| Cost of Revenue | $102.82M | $85.91M | $68.67M | $65.98M |
| Gross Profit | $490.35M | $415.01M | $591.15M | $428.36M |
| Gross Profit Ratio | $0.83 | $0.83 | $0.90 | $0.87 |
| R&D Expenses | $300.17M | $270.93M | $294.14M | $261.00M |
| SG&A Expenses | $295.34M | $220.99M | $248.40M | $210.80M |
| Operating Expenses | $595.51M | $491.92M | $542.54M | $471.79M |
| Total Costs & Expenses | $698.33M | $577.82M | $611.21M | $537.77M |
| Interest Income | $31.02M | $32.15M | $29.18M | $29.64M |
| Interest Expense | $38.97M | $34.38M | $33.26M | $35.25M |
| Depreciation & Amortization | $14.17M | $13.98M | $15.003M | $13.52M |
| EBITDA | -$140.82M | -$60.30M | $37.09M | -$14.82M |
| EBITDA Ratio | -$0.24 | -$0.12 | $0.06 | -$0.03 |
| Operating Income | -$105.16M | -$76.91M | $48.61M | -$43.44M |
| Operating Income Ratio | -$0.18 | -$0.15 | $0.07 | -$0.09 |
| Other Income/Expenses (Net) | -$88.80M | -$31.76M | -$59.78M | -$20.15M |
| Income Before Tax | -$193.96M | -$108.66M | -$11.17M | -$63.59M |
| Income Before Tax Ratio | -$0.33 | -$0.22 | -$0.02 | -$0.13 |
| Income Tax Expense | -$110.19M | $2.91M | $5.72M | $2.35M |
| Net Income | -$83.76M | -$111.57M | -$16.89M | -$65.94M |
| Net Income Ratio | -$0.14 | -$0.22 | -$0.03 | -$0.13 |
| EPS | -$0.65 | -$0.87 | -$0.13 | -$0.52 |
| Diluted EPS | -$0.65 | -$0.87 | -$0.13 | -$0.52 |
| Weighted Avg Shares Outstanding | $128.59M | $128.59M | $126.73M | $126.14M |
| Weighted Avg Shares Outstanding (Diluted) | $128.59M | $128.59M | $126.73M | $126.14M |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan